An experimental model of HIV infection in mice, developed by Mount Sinai researchers, has shown that HIV causes learning and memory dysfunction, a cognitive disease that is now observed in about half of HIV infected people that worsens with age, and is currently incurable.
Going on 20 years, the expertise of DIARECT AG is the design, manufacture and sales of recombinant and native antigens to the global IVD market. We provide our customers with over 150 antigens, and our product range is constantly expanding.
Going on 20 years, the expertise of DIARECT AG is the design, manufacture and sales of recombinant and native antigens to the global IVD market. We provide our customers with over 150 antigens, and our product range is constantly expanding.
Researchers at University of California San Diego School of Medicine discovered that they can block inflammation in mice with a naturally occurring antibody that binds oxidized phospholipids (OxPL), molecules on cell surfaces that get modified by inflammation. Even while on a high-fat diet, the antibody protected the mice from arterial plaque formation, hardening of the arteries and liver disease, and prolonged their lives.
Copper exposure’s link Alzheimer’s disease, the effects of consumer microbials on the colon, a potential prostate-based activation of a carcinogen in cooked meat, and the impact of hydraulic fracturing mixtures on the immune system featured in latest issue of Toxicological Sciences.
International experts delve into the latest advances in hormone research and clinical care on the Endocrine Society’s new podcast, which launches today.
By instructing key immune system cells to accept transplanted insulin-producing islets, researchers have opened a potentially new pathway for treating type 1 diabetes. If the approach is ultimately successful in humans, it could allow type 1 diabetes to be treated without the long-term complications of immune system suppression.
For 19 years, Lisa Thomas, former professional basketball player and Cedars-Sinai laboratory investigator of inflammatory bowel disorders and immunobiology, thought her glory days as a forward and center for collegiate and professional teams were behind her. And then she got a phone call that returned her to the hardwood courts of her youth. On June 9, Thomas will be one of 96 players from the now-defunct Women’s Professional Basketball League to be inducted as “Trailblazers” into The Women’s Basketball Hall of Fame.
A new study by University of North Carolina School of Medicine researchers has found that T cells, a type of white blood cell and an essential part of the immune system, are sufficient by themselves to establish and maintain an HIV infection in the brain.
Wistar and Harbour BioMed announce they have entered into a multi-year, multifaceted research collaboration to co-discover novel antibodies for the treatment of cancer and infectious diseases.
Haipeng Liu, Ph.D., assistant professor of chemical engineering at Wayne State University, received a Faculty Early Career Development (CAREER) award from the National Science Foundation to fund his research on vaccine adjuvants that can improve the treatment and care of cancer patients.
Epitope Diagnostics is proud to introduce a new adrenocortocotropic hormone (ACTH) ELISA Kit, which measures ACTH levels with high sensitivity and robust assay performance characteristics.
A UCLA-led study has found how colon cancer alters its genes during development in order to avoid detection by the immune system, creating a specific genetic imprint in the process.
Virginia Governor Ralph Northam will visit the Focused Ultrasound Foundation to discuss the impact of the State’s investment in pioneering this revolutionary technology. Invited guests will include the media, Foundation Board members, physicians and health industry leaders, and Foundation friends and supporters.
Rutgers Global Health Institute’s director discusses how rejecting scientific facts can undermine progress in public health – and how the medical profession can further public understanding of science
In an international Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with the oral FGFR inhibitor erdafitinib (ERDA) was well-tolerated and achieved a robust response for patients with metastatic urothelial, or urinary tract, cancers harboring mutations in the FGFR3 gene.
Roswell Park Comprehensive Cancer Center researchers have identified significant differences in the immune microenvironment of breast cancer tumors between African-American and white women, shedding light on the ways in which race can influence cancer development and outcomes. The findings, to be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, are based on based on a comprehensive review of data from The Cancer Genome Atlas.
Presenting new data at ASCO 2018, collaborators from Roswell Park Comprehensive Cancer Center, the Cleveland Clinic and MimiVax LLC report that the combination of SurVaxM plus standard therapy for patients with glioblastoma appears to be safe, effective and worthy of further evaluation.
The latest research and features in cell biology in the Cell Biology News Source
Scientists from the Sidney Kimmel Cancer Center (SKCC) at Jefferson Health will be presenting research and leading discussions on various topics, including metastatic uveal melanoma, genetic counseling in men, immunotherapy in early stage lung cancer and solid tumors, quality of life among patients receiving treatment for T cell lymphoma and updates on the Cancer Moonshot during the Biden Cancer Initiative Colloquium at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5 in Chicago.
At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, researchers from Cleveland Clinic Cancer Center will present data from several new studies, including a prospective clinical trial examining non-small cell lung cancer cells’ response to immunotherapy; research on germline testing for melanoma; and interim results from a study testing a vaccine for glioblastoma.
A new study shows that people who take drugs that suppress the immune system are less likely to develop Parkinson's disease, which is characterized by difficulty with movement.
St. Jude Children’s Research Hospital researchers have used systems biology approaches to reveal key details about regulation of immune function, including T cells that are central to cancer immunotherapy
Researchers at the University of Pennsylvania’s Abramson Cancer Center say a patient treated for chronic lymphocytic leukemia (CLL) in 2013 went into remission because of a single CAR T cell and the cells it produced as it multiplied, and has stayed cancer free in the five years since, with CAR T cells still present in his immune system.
Dubbed “T-cell engaging bi-specific antibodies,” these cancer combatants attack malignant cells but leave healthy cells untouched.
A study showing that pneumococcal vaccination produces a lasting antibody response in preterm infants has been named winner of the inaugural ESPID-PIDJ Award, recognizing the best paper submitted to The Pediatric Infectious Disease Journal (PIDJ) by a member of The European Society for Paediatric Infectious Diseases (ESPID). The Pediatric Infectious Disease Journal, the official journal of the ESPID, is published in the Lippincott portfolio by Wolters Kluwer.
UC San Diego School of Medicine researchers found that treating mice with a single spinal injection of a protein called AIBP — and thus switching “off” TLR4, a pro-inflammatory molecule — prevented and reversed inflammation and cellular events associated with pain processing. As reported May 29 by Cell Reports, the treatment alleviated chemotherapy pain in mice for two months with no side effects.
In the journal Nature Communications, researchers report for a particular subset of lung cancer tumors, there is a high prevalence of immune cells called inflammatory monocytes. These immune cells, which normally help to build clotting scaffolds to promote wound healing, also make it possible for tumor cells to migrate and spread to other parts of the body.
Newly published report in Nature Reviews Drug Discovery that provides a comprehensive, independent analysis of the global landscape of cancer cell therapies, including all agents from preclinical to post-market stages.
Fred Hutchinson Cancer Research Center’s latest findings will be featured at the annual meeting of the American Society of Clinical Oncology, “Delivering Discoveries: Expanding the Reach of Precision Medicine,” to be held June 1–5 in Chicago. Here are several highlights:
Researchers at the University of Michigan Rogel Cancer Center have discovered that tumor cells reprogram metabolic pathways to gain control over a type of immune cell that allows cancer growth.
Hematopoietic Stem Cells (HSCs) give rise to blood and immune cells of the body, and are therefore essential for our survival. They are in a dormant state, but whenever new blood needs to be formed, such as after blood loss or chemotherapy, they are rapidly activated to compensate for the loss. After completing their mission, they need to go back to their dormant state. The group of Manuela Baccarini at the Max F. Perutz Laboratories, a joint venture of the University of Vienna and the Medical University of Vienna, has now shown how intracellular signalling can safeguard this delicate balance between activation and dormancy. Their results are published in the prominent journal Cell Stem Cell.
An article published in Annals of Allergy, Asthma and Immunology shows allergies can have serious, far-reaching consequences, especially on adolescent sufferers.
With the recently announced FDA approval of Kymriah to treat adults with lymphoma, the University of Michigan Rogel Cancer Center is the first center in Michigan to offer all currently available CAR T-cell therapies.
A new discovery about how the immune system responds to common sinus infections and asthma could explain why patients develop these issues in the first place and ultimately may lead to improved targeted therapies.
Targeted cancer immunotherapy with irradiated, granulocyte–macrophage colony-stimulating factor (GM-CSF)-secreting, allogeneic cancer cell lines has been an effective approach to reduce tumor burden in several patients. A new paper in the Frontiers in Immunology highlights GM-CSF ability to shrink breast cancer tumors.
New research shows how some harmful microbes in the soil have to contend not just with a farmer’s chemical attacks, but also with their microscopic neighbors — and themselves turn to chemical warfare to ward off threats.
Recent research from Houston Methodist Hospital showed that a new immunotherapy was safe for patients with ALS and also revealed surprising results that could bring hope to patients who have this relentlessly progressive and fatal disease.
Journalists and bloggers are invited to join top scientists and practitioners as they discuss the latest nutrition research findings during Nutrition 2018, the inaugural flagship meeting of the American Society for Nutrition. The meeting will be held June 9-12, 2018 at the Hynes Convention Center in Boston.
In the journal Cancer Research, UNC Lineberger Comprehensive Cancer Center researchers report they have developed a model of luminal bladder cancer, one of the two subtypes of advanced bladder cancer. The researchers said this model may help them to determine which patients may respond to checkpoint inhibitors.
FINDINGS UCLA-led research suggests that receiving support from friends and acquaintances can help prevent black men who have sex with men from becoming infected with HIV. BACKGROUND Black men who have sex with men have disproportionately high rates of HIV infection. While social connections are known to influence the behaviors that influence people’s risk for HIV, little is known about whether they affect the risk for becoming infected with HIV.
Month-long awareness and education campaign in June highlighting breakthroughs in cancer treatment with immunotherapy and the urgent need for more research funding
Drug-resistant staph infections continue to be deadlier than those that are not resistant and treatable with traditional antibiotics, but treatment costs surprisingly are the same or slightly less, a new national analysis shows.
The battle between the human immune system and long-term, persisting infections and other chronic diseases such as cancer results in a prolonged stalemate. Over time battle-weary T cells become exhausted, giving germs or tumors an edge. Using data from multiple molecular databases, researchers have found nine distinct types of exhausted T cells, which could have implications for fighting chronic infections, autoimmunity, and cancer.
Using new analytic tools, researchers at University of California San Diego School of Medicine and the Icahn School of Medicine at Mount Sinai have decoded the epigenetic landscape for rheumatoid arthritis (RA), a common autoimmune disease that affects more than 1.3 million Americans.
The clinical trial attempts to persistently lower the serum uric acid level in patients.
Research conducted in vitro shows two human antibodies made in response to vaccination against one hemorrhagic fever virus can disarm a related virus, for which there is currently no vaccine. The proof-of-principle finding identifies a common molecular chink in the two viruses’ armor that renders both vulnerable to the same antibodies. The results set the stage for a single vaccine and other antibody-based treatments that work against multiple viral “cousins” despite key differences in their genetic makeup. Such therapies can alleviate challenges posed by current lack of vaccines and prevent outbreaks of viral hemorrhagic fevers.
Click here to go directly to the Cancer News Source
Recent studies in the journal Molecular & Cellular Proteomics have shed light on pathogenic mechanisms of the sexually-transmitted parasite Trichomonas vaginalis and the HIV-associated opportunistic lung fungus Aspergillus.
Anthrax, plague and tularemia are three potent agents terrorists would be likely to use in an attack, according to the Centers for Disease Control and Prevention. Each is highly and quickly lethal to humans. But there are no licensed vaccines for tularemia and plague, and although there is an anthrax vaccine, it requires a burdensome immunization schedule and has severe side effects.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right